Recent Episodes
-
349: BIO's John Crowley on RFK Jr. and tariffs, plus calls for more federal biotech funding
Apr 10, 2025 – 40:55 -
348: Cuts, ousters and drama at the FDA
Apr 3, 2025 – 31:10 -
347: More HHS upheaval, 23andMe's bankruptcy, and AI for cancer survival
Mar 27, 2025 – 31:25 -
346: Zealand's obesity strategy and Immunovant's curious development plan
Mar 20, 2025 – 42:34 -
345: The sudden withdrawal of a CDC nominee and what went wrong with Covid policies
Mar 13, 2025 – 31:00 -
344: Trump's FDA commissioner nominee takes the hot seat
Mar 6, 2025 – 25:51 -
343: Turbulence at the FDA, Bluebird Bio's sale and young biotech VCs
Feb 27, 2025 – 32:01 -
342: FDA cuts, zombie biotechs, and too much weight loss?
Feb 20, 2025 – 41:00 -
341: NIH funding cuts, a U.S. brain drain, and bold claims from AI drug developers
Feb 13, 2025 – 26:39 -
340: Crisis in CRISPR world, RFK Jr.'s promises, and a novel non-opioid pain drug
Feb 6, 2025 – 34:45 -
339: RFK Jr.'s confirmation hearings, MASH drugs, and a controversial obesity ad
Jan 30, 2025 – 34:29 -
338: Chinese biotechs, a WHO departure, and post-JPM thoughts
Jan 23, 2025 – 33:09 -
337: Eli Lilly CEO on Trump, obesity drugs, and a guidance miss
Jan 15, 2025 – 58:47 -
336: Pharma's big patent cliff, more obesity fundraising, and a failed ALS study
Jan 9, 2025 – 33:21 -
335: A deep dive on Makary, Vertex's pain data, & 2025 predictions
Dec 19, 2024 – 33:43 -
334: Pharma silence on RFK Jr. & parents trying to develop gene therapies for their children
Dec 12, 2024 – 34:30 -
333: An H5N1 bird flu update and talent scarcity in the radiopharma field
Dec 5, 2024 – 27:55 -
332: Pfizer's new R&D head, a VC deep-dive, and a new FDA commissioner?
Nov 21, 2024 – 35:08 -
331: AbbVie’s stumble, Amgen’s tumble and more election fallout
Nov 14, 2024 – 30:16 -
330: How a Trump presidency could affect the FDA, the biotech industry, and its stocks
Nov 7, 2024 – 39:22 -
329: Lilly's earnings surprise, investors mull the election, & a spooky ghost story
Oct 31, 2024 – 28:25 -
328: Pfizer's activist troubles, gene therapy questions, RFK Jr.'s MAHA ambitions
Oct 24, 2024 – 33:46 -
327: Biotech's next gold rush, GLP-1 shortages, and STAT Summit highlights
Oct 17, 2024 – 34:19 -
326: Crypto for CRISPR, a new RNAi startup, & a Nobel for AI
Oct 10, 2024 – 40:08 -
325: Biden's health care AI czar, a new obesity company, and its dealmaking CEO
Oct 3, 2024 – 32:48 -
From Tradeoffs: Race to the Bottom
Sep 28, 2024 – 28:08 -
324: Genentech's cancer pivot, Pfizer's sickle cell withdrawal, and a new schizophrenia drug
Sep 26, 2024 – 32:02 -
323: Cannabinoids for weight loss, a cancelled ad comm, and the Fed lowers interest rates
Sep 19, 2024 – 35:21 -
322: A new threat to Merck's blockbuster cancer treatment, Moderna's cutbacks, and obesity drugs for kids
Sep 12, 2024 – 32:57 -
321: Summit's upcoming cancer results, Recursion's mixed data, and the next big obesity target
Sep 5, 2024 – 35:18 -
320: Jim Wilson's next venture, a surprise startup shutdown, & Lilly's Zepbound strategy
Aug 29, 2024 – 37:34 -
From "Say More": What Happens When AI Decides Your Medical Coverage
Aug 23, 2024 – 22:42 -
319: BioMarin's executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion's AI bona fides
Aug 22, 2024 – 34:07 -
318: Drug pricing drops & psychedelics under fire
Aug 15, 2024 – 21:16 -
317: VC struggles, drug pricing negotiations, & Novo's abrupt Wegovy decision
Aug 8, 2024 – 28:52 -
316: The long journey to make malaria vaccines, and Sarepta's ties with patient advocates
Aug 1, 2024 – 34:15 -
315: UnitedHealth's doctor empire, an FDA departure, and Viking's obesity moves
Jul 25, 2024 – 32:46 -
314: JD Vance's biotech ties, Cassava resignations, and insulin shortages
Jul 18, 2024 – 33:02 -
313: Biotech layoffs, founder-focused VC, & a big pharma exit
Jul 11, 2024 – 34:52 -
312: Medicare coverage for GLP-1 drugs, AI, and health care at the presidential debate
Jun 27, 2024 – 28:33 -
311: Fauci's memoir, Alnylam's tenuous trial, and a mid-year review
Jun 20, 2024 – 34:10 -
310: Duchenne gene therapy setback, Alzheimer's drug endorsement & why a STAT reporter buys weed (for journalism)
Jun 13, 2024 – 38:46 -
309: Psychedelics at the FDA, ASCO recap, & MorphoSys update
Jun 6, 2024 – 29:34 -
308: An ASCO preview & another Duchenne trial failure
May 30, 2024 – 28:34 -
307: More tumult at BIO & coercive care for sickle cell patients
May 23, 2024 – 31:07 -
306: Live! From the STAT Breakthrough Summit West
May 16, 2024 – 23:08 -
305: Everything you need to know about H5N1 bird flu
May 9, 2024 – 31:52 -
304: Controversial brain tissue research, obesity drug sales and Novartis’ M&A drama
May 2, 2024 – 33:04 -
303: A new obesity startup, an acquisition gone wrong, & the future of Teledoc
Apr 18, 2024 – 31:45 -
302: Vertex's big deal, biotech's red numbers, & an industry history lesson
Apr 11, 2024 – 24:48
Recent Reviews
-
bennoanddixieYour bias is showingDisappointing that your reporting of the DHHS staff cuts (and the new administration as a whole) is so one-sided. How about trying a neutral approach? Consider that some of your listeners have common sense.
-
MilesMcKinleyThe best podcast out thereThis podcast will blow your mind, five stars
-
HB4000Great podcastIt helps me catch up on the biotech news every week! Very informative.
-
Miss_PrismPervaded by a haughty……treacle-y, leftist tone of contempt for critics of the COVID lockdowns and the patently inane government mask mandates, and bogus wet market theory, as to which the critics were right, and the government mired in cover-up, wrong. NPR-ish sneering and attitudinalizing that communicates little to no substance.
-
Dougie McIntoshGreat showLove the podcast but if you’re going to give spoilers for GBB, please give a warning so those who haven’t seen it yet can skip the segment!
-
AshokaMadduriBest podcast of BioPharmaThis is the best podcast for anyone interested in biotech, pharmaceutical & healthcare news. It seamlessly covers all the key industry updates and brings important topics to light. I love how casually and engagingly the hosts discuss a well-curated range of subjects, making complex news accessible and enjoyable to follow!
-
zoey1926Not a fan of host style but ok contentTried out a few episodes, not a big fan, there are too many “you know” “uh” filler words during speech I am not a big fan. Content is ok, talking about relevant stuff but you can tell there are topics they lack confidence, not well researched.
-
dharma mattGenerally goodI like their summaries it keeps me in the loop. But boy were they clueless on all things Covid and really did society a disservice by being a mouthpiece for public health instead of challenging obviously bad policy. Hope they do an introspective review one day and come clean
-
WndyGGood but could be betterThis podcast does a good job of tackling developments in Biotech and boiling down complex subjects into cliff notes versions for listeners who want to get a quick overview of what is happening in the industry. The hosts are smart and entertaining but can be overly judgmental and “know-it-alls” in their commentary. After all, they are reporting on brilliant innovation and amazing science, not actually creating brilliant innovation and amazing science.
-
Two gluonHosts have technical knowledge but could benefit from journalism or communications coursesI want to dive deeper into the pharma market, and this podcast helps get there maybe 65% of the way. My issue is that some (not all) of the hosts can be very inarticulate. Sometimes there’s a lot of stuttering or awkward pauses as they communicate their thoughts. It can come across as them being unprepared — which maybe is the format?
-
C4l71nGreat PodcastAmazing content — the podcast hosts really understand the biopharma field (both the science and history) and their jokes are also quite funny.
-
Listner No.1Good podcast but that theme songGreat content, smart hosts but that theme song/intro is jarring and amateurish.
-
OncoproteinsFantastic podcast!Absolutely thrilled about this phenomenal podcast centered on pharma and biotech news! Weekly episodes are fantastic, though I’d be over the moon if they could dive even deeper and extend the show’s length. Keep up the awesome work! Welcome back, Allison (DeAngelis)!
-
SlivryGreat podcast!Great podcast! Focus on news and not sales pitch like interviews such as that recent Novovax piece. Keep up the good work!
-
H broganAbsolutely horrific and harmful to the advances in medicineThis podcast, stat news, and Adam Feuerstein are absolutely harmful to the advances in medicine. Make sure if listening to this GARBAGE you go and check your facts. It’s dangerous to listen to this company’s and their reporters opinions without doing your DD.
-
Ginagina SmithWelcome back, Meg!We need quality masks that don’t leave lines ! I have that problem & hate it.
-
reportinghygeineWrong Tone On the Murder for HireIt sounds like someone was killed. If it was one of your close relatives you would be furious about the tone. Murder is serious, not funny, although I do understand that it’s not usually your beat. You come off as young, naive and lacking in character and wisdom.
-
ocean 1435🐾Love thisHi i love the podcast❤️❤️❤️❤️❤️❤️
-
CxxxxLxxxxxGreat for people who follow the biotech industryDoes a great job of reporting on and discussing the important developments in the biotech industry.
-
x-x-x-x-x-cDon’t recommend if your not over 25I just couldn’t stand to listen to this person
-
JabittanGreat Science & Bio Check-InListen every week and love the insights and updates! Always great music throughout as well
-
mas13128234FueursteinIs an unbearable snob
-
cmc4648Great reportersIt’s obvious the hosts of this podcast are working reporters, and good ones at that. The show topics are exactly what I want to know about biotech each week. I’m also a big fan of the “chatty Cathy” segment.
-
Long time in ChinaExcellentHighly quality podcast
-
liviayyyyyBest biotech podcast everLove love this podcast! Wanted to to find something similar for a long time! I am glad I was able to find this podcast. The hosts are so knowledgeable and articulate. Good flow, interesting story, and wonderful people! I just want more! Maybe twice a week?
-
mbh1959My go to podcast to stay updated on current trendsThe Readout always covers a broad array of disease states and updates. I teach drug discovery at a university and it is always helpful to get quick high level updates on the field.
-
dtracy44Thank You - Remembering SharonThank you for a great tribute to Sharon and not only her work but as a person. STAT+ team you paid a wonderful tribute here.
-
alex*1*Great thematic reportingStrong themes, narratives, and timely relevance.
-
HTBackpackerEpisode 127 Most timely!One of your best ever!!!
-
ColestirFake newsThought this was a medical podcast where I thought I could get some info on different biotech companies fighting Covid 19. Found out it was just a liberal Trump bash.
-
pgcglassgirlGreat biotech/pharma overviewI started listening to this podcast while preparing to make a career pivot into biotech/pharma during business school and gearing up for interviews. Alongside the STAT email newsletters and STAT+ membership, this podcast helped me feel so much more confident about understanding these industries and keeping track of key company news. Now, I’m an MBA intern working in biotech and continue to love keeping up with what’s going on in the industry with Adam, Rebecca, and Matt!
-
Iowa ProcessingGreat podcastReally great content. It’s very informative even to myself as someone who isn’t in the medical field. Lots of good info and a calm informative tone
-
orange-juicerGood, Quick CatchupThanks for the stories and interviews! Well-researched and balanced reporting.
-
cantfindnick!!!Love love loveThis podcast is beautifully structured, interesting, great stories , great sound. It shows that a lot of thought and effort is put into it. Too bad it’s broadcasted only once a week...
-
TinattttMy favorite podcast!Love being able to catch up on the road. Best I could find. Thank you!
-
EsvrdschExcellent!One of the few places to hear biotech insiders and experts share their thoughts. Keep up the great reporting!
-
bluemeaniefaceThreadbareThey’re going through the motions of producing an NPR/KCRW edited news report but you leave with 10 times more questions than answers. It’s foreplay for the next podcast or article you find that actually tackles the subject. Kids in their parents clothing. Do something original or at least do something complete. Theranos story was unbelievable. I still have no idea what the actual story is. Why are you podcasting? Go start a book club.
-
3063819Best Biotech Podcast!Great for the nerd, investor or both! Always look forward to Thursday! Would love to hear more about “deep dive” diagnostics companies and how the info is used to avoid unnecessary procedures. Thinking of Invitae, Veracyte, etc...
-
tailormadewellNice podcast, good guestsOverall very nice podcast, good review of the weekly biotech news that is good for someone in the go who doesn’t have time to read the news/blogs/journals. BUT they use the word “frothy” WAY TOO MUCH. Can’t you think of a different descriptor?
-
MannyTZGreat podcast for Pharma / Biotech execsBest podcast out there for industry folks. Short but extremely informative. Highly recommend.
Similar Podcasts
Disclaimer: The podcast and artwork on this page are property of the podcast owner, and not endorsed by UP.audio.